Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia

Tools

Item Type:	Article
Title:	Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia
Creators Name:	Kaeda, J., Ringel, F., Oberender, C., Mills, K., Quintarelli, C., Pane, F., Koschmieder, S., Slany, R., Schwarzer, R., Saglio, G., Hemmati, P., van Lessen, A., Amini, L., Greese, M., Vagge, E., Burmeister, T., Serra, A., Carson, A., Schwarz, M., Westermann, J., Jundt, F., Doerken, B. and le Coutre, P.
Abstract:	A better understanding of events triggering chronic myeloid leukemia progression is critical for optimized clinical management of chronic myeloid leukemia (CML). We sought to validate that increased expression of Musashi 2 (MSI2), a post-transcription regulator, is associated with progression and prognosis. Screening of 152 patients with CML showed that MSI2 was significantly decreased among patients with CML in chronic phase (CP) at diagnosis (p < 0.0001), but found no significant difference between the normal control group and treated patients with CML in CP. Moreover MSI2 was significantly increased (p < 0.0001) in patients with advance disease (AD) CML. Furthermore, our human hematopoietic cell line data imply that MSI2 and BCR-ABL1 mRNA expression are correlated. However, these data cast a doubt on earlier reports that MSI2 effects HES1 expression via NUMB–NOTCH signaling.
Keywords:	Prognosis, Transformation, MSI2, Leukemia, Stem Cell
Source:	Leukemia & Lymphoma
ISSN:	1042-8194
Publisher:	Informa Healthcare
Volume:	56
Number:	7
Page Range:	2105-2113
Date:	July 2015
Official Publication:	https://doi.org/10.3109/10428194.2014.981175
PubMed:	View item in PubMed

Repository Staff Only: item control page